Cargando…

T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern

The progression of the COVID-19 pandemic has led to the emergence of variants of concern (VOC), which may compromise the efficacy of the currently administered vaccines. Antigenic drift can potentially bring about reduced protective T cell immunity and, consequently, more severe disease manifestatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Hila, Rotem, Shahar, Elia, Uri, Bilinsky, Gal, Levy, Itzchak, Chitlaru, Theodor, Bar-Haim, Erez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878189/
https://www.ncbi.nlm.nih.gov/pubmed/35215940
http://dx.doi.org/10.3390/v14020347
_version_ 1784658602936500224
author Cohen, Hila
Rotem, Shahar
Elia, Uri
Bilinsky, Gal
Levy, Itzchak
Chitlaru, Theodor
Bar-Haim, Erez
author_facet Cohen, Hila
Rotem, Shahar
Elia, Uri
Bilinsky, Gal
Levy, Itzchak
Chitlaru, Theodor
Bar-Haim, Erez
author_sort Cohen, Hila
collection PubMed
description The progression of the COVID-19 pandemic has led to the emergence of variants of concern (VOC), which may compromise the efficacy of the currently administered vaccines. Antigenic drift can potentially bring about reduced protective T cell immunity and, consequently, more severe disease manifestations. To assess this possibility, the T cell responses to the wild-type Wuhan-1 SARS-CoV-2 ancestral spike protein and the Omicron B.1.1.529 spike protein were compared. Accordingly, peripheral blood mononuclear cells (PBMC) were collected from eight healthy volunteers 4–5 months following a third vaccination with BNT162b2, and stimulated with overlapping peptide libraries representing the spike of either the ancestral or the Omicron SARS-CoV-2 virus variants. Quantification of the specific T cells was carried out by a fluorescent ELISPOT assay, monitoring cells secreting interferon-gamma (IFNg), interleukin-10 (IL-10) and interleukin-4 (IL-4). For all the examined individuals, comparable levels of reactivity to both forms of spike protein were determined. In addition, a dominant Th1 response was observed, manifested mainly by IFNg-secreting cells and only limited numbers of IL-10- and IL-4-secreting cells. The data demonstrate stable T cell activity in response to the emerging Omicron variant in the tested individuals; therefore, the protective immunity to the variant following BNT162b2 vaccination is not significantly affected.
format Online
Article
Text
id pubmed-8878189
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88781892022-02-26 T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern Cohen, Hila Rotem, Shahar Elia, Uri Bilinsky, Gal Levy, Itzchak Chitlaru, Theodor Bar-Haim, Erez Viruses Brief Report The progression of the COVID-19 pandemic has led to the emergence of variants of concern (VOC), which may compromise the efficacy of the currently administered vaccines. Antigenic drift can potentially bring about reduced protective T cell immunity and, consequently, more severe disease manifestations. To assess this possibility, the T cell responses to the wild-type Wuhan-1 SARS-CoV-2 ancestral spike protein and the Omicron B.1.1.529 spike protein were compared. Accordingly, peripheral blood mononuclear cells (PBMC) were collected from eight healthy volunteers 4–5 months following a third vaccination with BNT162b2, and stimulated with overlapping peptide libraries representing the spike of either the ancestral or the Omicron SARS-CoV-2 virus variants. Quantification of the specific T cells was carried out by a fluorescent ELISPOT assay, monitoring cells secreting interferon-gamma (IFNg), interleukin-10 (IL-10) and interleukin-4 (IL-4). For all the examined individuals, comparable levels of reactivity to both forms of spike protein were determined. In addition, a dominant Th1 response was observed, manifested mainly by IFNg-secreting cells and only limited numbers of IL-10- and IL-4-secreting cells. The data demonstrate stable T cell activity in response to the emerging Omicron variant in the tested individuals; therefore, the protective immunity to the variant following BNT162b2 vaccination is not significantly affected. MDPI 2022-02-08 /pmc/articles/PMC8878189/ /pubmed/35215940 http://dx.doi.org/10.3390/v14020347 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Cohen, Hila
Rotem, Shahar
Elia, Uri
Bilinsky, Gal
Levy, Itzchak
Chitlaru, Theodor
Bar-Haim, Erez
T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern
title T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern
title_full T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern
title_fullStr T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern
title_full_unstemmed T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern
title_short T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern
title_sort t cell response following anti-covid-19 bnt162b2 vaccination is maintained against the sars-cov-2 omicron b.1.1.529 variant of concern
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878189/
https://www.ncbi.nlm.nih.gov/pubmed/35215940
http://dx.doi.org/10.3390/v14020347
work_keys_str_mv AT cohenhila tcellresponsefollowinganticovid19bnt162b2vaccinationismaintainedagainstthesarscov2omicronb11529variantofconcern
AT rotemshahar tcellresponsefollowinganticovid19bnt162b2vaccinationismaintainedagainstthesarscov2omicronb11529variantofconcern
AT eliauri tcellresponsefollowinganticovid19bnt162b2vaccinationismaintainedagainstthesarscov2omicronb11529variantofconcern
AT bilinskygal tcellresponsefollowinganticovid19bnt162b2vaccinationismaintainedagainstthesarscov2omicronb11529variantofconcern
AT levyitzchak tcellresponsefollowinganticovid19bnt162b2vaccinationismaintainedagainstthesarscov2omicronb11529variantofconcern
AT chitlarutheodor tcellresponsefollowinganticovid19bnt162b2vaccinationismaintainedagainstthesarscov2omicronb11529variantofconcern
AT barhaimerez tcellresponsefollowinganticovid19bnt162b2vaccinationismaintainedagainstthesarscov2omicronb11529variantofconcern